Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 501–600 of 1,082
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer
Feagins, L. A., Souza, R. F., & Spechler, S. J. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.44 · Cited by 274
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
Ng, E. W. M., & Adamis, A. P. (2005) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(05)80078-x · Cited by 273
l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth
Oda, K., Hosoda, N., Endo, H., Saito, K., Tsujihara, K., Yamamura, M., Sakata, T., Anzai, N., Wempe, M. F., Kanai, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01386.x · Cited by 273
Anjum, K., Shagufta, B. I., Abbas, S. Q., Patel, S., Khan, I., Shah, S. A. A., Akhter, N., & Hassan, S. S. U. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.125 · Cited by 271
RetractedCancer stem cells: implications for the progression and treatment of metastatic disease
Croker, A. K., & Allan, A. L. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00211.x · Cited by 273
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Nordlinger, B., Van Cutsem, E., Rougier, P., Köhne, C.-H., Ychou, M., Sobrero, A., Adam, R., Arvidsson, D., Carrato, A., Georgoulias, V., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.017 · Cited by 272
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., Schultz, L., & Mikkelsen, T. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9718-y · Cited by 272
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
Bouché, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guérin-Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 274
Differentiation and Definition of Vascular-Targeted Therapies
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D., & LoRusso, P. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.416.11.2 · Cited by 272
Goéré, D., Malka, D., Tzanis, D., Gava, V., Boige, V., Eveno, C., Maggiori, L., Dumont, F., Ducreux, M., & Elias, D. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31827e9289 · Cited by 272
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.12.013 · Cited by 270
Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Eguchi Nakajima, T., Baba, E., Tsuda, M., Moriwaki, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw206 · Cited by 268
A targeted approach to cancer imaging and therapy
Li, C. (2014) · Nature Materials · doi:10.1038/nmat3877 · Cited by 268
Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P., & Pili, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1132 · Cited by 268
Lubner, S. J., Mahoney, M. R., Kolesar, J. L., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W.-P., Horvath, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression
Pal, S. K., & Hurria, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0579 · Cited by 265
Li, J., Zhao, X., Chen, L., Guo, H., Lv, F., Jia, K., Yv, K., Wang, F., Li, C., Qian, J., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-529 · Cited by 265
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Berber, E., Pelley, R., & Siperstein, A. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.039 · Cited by 264
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260
Vascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Takahashi, S. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1785 · Cited by 261
Poston, G. J., Adam, R., Alberts, S., Curley, S., Figueras, J., Haller, D., Kunstlinger, F., Mentha, G., Nordlinger, B., Patt, Y., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.722 · Cited by 260
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S. H., Petrelli, N. J., Goldberg, R. M., Atkins, J. N., Seay, T. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9220 · Cited by 262
Self-citationSong, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W., Boonsirikamchai, P., Choi, H., Wang, X., et al. (2011) · Cancer · doi:10.1002/cncr.26098 · Cited by 261
Role of surgery in colorectal cancer liver metastases
Akgül, Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6113 · Cited by 259
Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C., Jackson, E., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Dancey, J. E., Dobbin, K. K., Groshen, S., Jessup, J. M., Hruszkewycz, A. H., Koehler, M., Parchment, R., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 258
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)
JORGE, R., COSTA, R. A., CALUCCI, D., CINTRA, L. P., & SCOTT, I. U. (2006) · Retina · doi:10.1097/01.iae.0000246884.76018.63 · Cited by 258
Colevas, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3348 · Cited by 257
Kodjikian, L., Souied, E. H., Mimoun, G., Mauget-Faÿsse, M., Behar-Cohen, F., Decullier, E., Huot, L., & Aulagner, G. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.020 · Cited by 257
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
van der Pool, A. E. M., Damhuis, R. A., IJzermans, J. N. M., de Wilt, J. H. W., Eggermont, A. M. M., Kranse, R., & Verhoef, C. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02539.x · Cited by 257
Kindler, H. L., Karrison, T. G., Gandara, D. R., Lu, C., Krug, L. M., Stevenson, J. P., Jänne, P. A., Quinn, D. I., Koczywas, M. N., Brahmer, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5869 · Cited by 257
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing
Amin, E. M., Oltean, S., Hua, J., Gammons, M. V. R., Hamdollah-Zadeh, M., Welsh, G. I., Cheung, M.-K., Ni, L., Kase, S., Rennel, E. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.016 · Cited by 253
Gillams, A. R., & Lees, W. R. (2009) · European Radiology · doi:10.1007/s00330-008-1258-5 · Cited by 254
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., et al. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1171 · Cited by 253
Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., & Kerbel, R. S. (2005) · Blood · doi:10.1182/blood-2005-04-1422 · Cited by 253
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 249
“…for most mCRC have remained limited to chemotherapy for decades, whereas the inclusion of targeted therapies against the endothelial growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) signalling pathways has only improved outcomes in some groups of patients 3,4 .”
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Abdel-Qadir, H., Ethier, J.-L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.002 · Cited by 251
Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00042-x · Cited by 251
The history of the angiogenic switch concept
Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M., & Vacca, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404402 · Cited by 250
Grothey, A., & Sargent, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4792 · Cited by 252
Spano, J.-P., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H., Barone, C., Létourneau, R., Bajetta, E., Pithavala, Y., Bycott, P., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60661-3 · Cited by 250
Sorafenib in Advanced Hepatocellular Carcinoma
(2008) · New England Journal of Medicine · doi:10.1056/nejmc081780 · Cited by 250
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
Strumberg, D., Scheulen, M. E., Schultheis, B., Richly, H., Frost, A., Büchert, M., Christensen, O., Jeffers, M., Heinig, R., Boix, O., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.153 · Cited by 249
Cellular and molecular pathways linking inflammation and cancer
Porta, C., Larghi, P., Rimoldi, M., Grazia Totaro, M., Allavena, P., Mantovani, A., & Sica, A. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.014 · Cited by 250
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Madu, C. O., Wang, S., Madu, C. O., & Lu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.44313 · Cited by 249
Vascular endothelial growth factor receptor-2 in breast cancer
Guo, S., Colbert, L. S., Fuller, M., Zhang, Y., & Gonzalez-Perez, R. R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.04.004 · Cited by 246
Horsman, M. R., & Siemann, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2848 · Cited by 246
Le Tourneau, C., Raymond, E., & Faivre, S. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.2.341 · Cited by 247
Targeting Src in breast cancer
Finn, R. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn291 · Cited by 248
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248
Bender, J. L. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney-Qualter, E. M., Stempak, D., Chen, H. X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9230 · Cited by 249
D'Angelica, M. I., Correa-Gallego, C., Paty, P. B., Cercek, A., Gewirtz, A. N., Chou, J. F., Capanu, M., Kingham, T. P., Fong, Y., DeMatteo, R. P., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000614 · Cited by 246
CCR4 as a novel molecular target for immunotherapy of cancer
Ishida, T., & Ueda, R. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00307.x · Cited by 247
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
Herbst, R. S., Onn, A., & Sandler, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.853 · Cited by 246
Lichtman, S. M., Wildiers, H., Launay-Vacher, V., Steer, C., Chatelut, E., & Aapro, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.004 · Cited by 245
Shen, L., Li, J., Xu, J., Pan, H., Dai, G., Qin, S., Wang, L., Wang, J., Yang, Z., Shu, Y., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0351-5 · Cited by 243
Gene therapy for cancer: present status and future perspective
Amer, M. H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-27 · Cited by 244
Guiu, B., Petit, J. M., Bonnetain, F., Ladoire, S., Guiu, S., Cercueil, J.-P., Krausé, D., Hillon, P., Borg, C., Chauffert, B., et al. (2010) · Gut · doi:10.1136/gut.2009.188946 · Cited by 245
Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
Lunenburg, C. A. T. C., van der Wouden, C. H., Nijenhuis, M., Crommentuijn-van Rhenen, M. H., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0540-0 · Cited by 242
Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0591 · Cited by 244
Rao, S., Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kourteva, G., Iveson, T., Andre, T., Dostalova, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.037 · Cited by 244
Sagar, S. M., Yance, D., & Wong, R. K. (2006) · Current Oncology · doi:10.3747/co.v13i1.77 · Cited by 243
Lucio-Eterovic, A. K., Piao, Y., & de Groot, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0575 · Cited by 243
Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17492 · Cited by 243
Systemic cancer therapy: achievements and challenges that lie ahead
Palumbo, M. O., Kavan, P., Miller, W. H., Panasci, L., Assouline, S., Johnson, N., Cohen, V., Patenaude, F., Pollak, M., Jagoe, R. T., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00057 · Cited by 241
S3-Leitlinie – Kolorektales Karzinom: Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., Nothacker, M., Porschen, R., Rödel, C., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 241
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
Chiorean, E. G., Nandakumar, G., Fadelu, T., Temin, S., Alarcon-Rozas, A. E., Bejarano, S., Croitoru, A.-E., Grover, S., Lohar, P. V., Odhiambo, A., et al. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00367 · Cited by 242
Bevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S. F., Compton, P., Huang, J., Augustus, S., & Rohr, U.-P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 241
Herbst, R. S., Hong, D., Chap, L., Kurzrock, R., Jackson, E., Silverman, J. M., Rasmussen, E., Sun, Y.-N., Zhong, D., Hwang, Y. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6683 · Cited by 241
Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma
Iliev, M. E., Domig, D., Wolf-Schnurrbursch, U., Wolf, S., & Sarra, G.-M. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.066 · Cited by 240
Sargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4323 · Cited by 240
COLLISION Trial Group, Puijk, R. S., Ruarus, A. H., Vroomen, L. G. P. H., van Tilborg, A. A. J. M., Scheffer, H. J., Nielsen, K., de Jong, M. C., de Vries, J. J. J., Zonderhuis, B. M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4716-8 · Cited by 240
Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239
Self-citationIrinotecan in the treatment of colorectal cancer
Fuchs, C., Mitchell, E. P., & Hoff, P. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.001 · Cited by 237
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
Wu, S., Kim, C., Baer, L., & Zhu, X. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020167 · Cited by 238
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-38 · Cited by 239
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Self-citationMasi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Del Monte, F., Cortesi, E., Amoroso, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
“No clinical subgroup (e.g., age, gender, performance status) appeared to benefit more or less from therapy (Kohne et al. 2002; Hurwitz et al. 2004).”
InfluentialSelf-citationProgrammed Translational Readthrough Generates Antiangiogenic VEGF-Ax
Eswarappa, S. M., Potdar, A. A., Koch, W. J., Fan, Y., Vasu, K., Lindner, D., Willard, B., Graham, L. M., DiCorleto, P. E., & Fox, P. L. (2014) · Cell · doi:10.1016/j.cell.2014.04.033 · Cited by 236
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 237
Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.036 · Cited by 237
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.